Harnessing the Power of AI: Optimizing Workflows & Enhancing Testing Across the Cancer Care Continuum

Dr. Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus’ leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as Hematology/Oncology Fellowship Program Director.

Dr. Kate Sasser is the Chief Scientific Officer of Tempus. Dr. Sasser brings over 20 years of experience in translational research and precision medicine in biological sciences across academia and the pharmaceutical and biotech industry. Prior to Tempus, she led the translational research, precision medicine, and R&D operations organizations within Genmab, a biotech company focused on developing transformative antibody therapeutics as medicine. She also led translational research for oncology at Johnson and Johnson (Janssen PRD), using translational and data science approaches to accelerate clinical development. Dr. Sasser graduated from Oregon State University with a BS in Microbiology, and received her PhD in integrated biomedical sciences from Ohio State University.

Dr. Parsons is a physician-scientist with more than 20 years of experience in designing, executing, and leading clinical trials in the private and public sectors. He has expertise in all phases of bench-to-beside biomedical research and is an author on over 190 scientific publications appearing in JAMA, the New England Journal of Medicine, Journal of Clinical Oncology, and others. He has served on national committees for the American Society of Clinical Oncology, National Comprehensive Cancer Network (Committee Co-chair), and American Urological Association (Committee Chair); in national leadership positions within the National Cancer Institute clinical trials network; and on the editorial boards of three medical journals. Prior to joining MBrace, he was Senior Medical Director at Janssen R&D. In this role, he supervised an international Phase 3 registrational oncology trial of 2,400 patients, co-led the development of a novel Phase 3 registrational study and corresponding Type C FDA interaction, and advised on Phase 1 through 3 clinical trial designs across the oncology solid tumor portfolio. Prior to Janssen, Dr. Parsons was an endowed Professor and Head of Urologic Oncology at the Moores UC San Diego Comprehensive Cancer Center. Dr. Parsons completed his residency in urologic surgery and fellowship in urologic oncology at the Johns Hopkins Hospital. He received his M.H.S. in Clinical Investigation from the Johns Hopkins Bloomberg School of Public Health, M.D. from the University of Pennsylvania, and A.B. in History from Stanford University.

Dr. Halla Nimeiri serves as the Chief Development Officer of Oncology at Tempus. Prior to Tempus, she held clinical development positions at Foundation Medicine and AbbVie. Dr. Nimeiri is a dedicated oncologist. She brings expertise in clinical trial design, drug development, and precision oncology. Dr. Nimeiri is an active academic clinician at Feinberg School of Medicine, where she provided transformative patient care for over 10 years. Dr. Nimeiri earned her dual fellowship in Hematology/Oncology from The University of Chicago.